CLINICAL TRIALS PROFILE FOR MAXIPIME

All Clinical Trials for MAXIPIME

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Clinica Palermo, Bogota	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Fundación San Carlos, Bogota	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Hospital san Jorge, Pereira	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗	Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen	Completed	Hospital san Juan de Dios, Antioquia	Phase 4	2006-09-01	To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.

Clinical Trial Conditions for MAXIPIME

Condition Name

Condition Name for MAXIPIME
Intervention	Trials
Sepsis	1
Chronic Lymphocytic Leukemia	1
Grade 3 Follicular Lymphoma	1
Adult Diffuse Large Cell Lymphoma	1

Condition MeSH

Condition MeSH for MAXIPIME
Intervention	Trials
Urinary Tract Infections	2
Infections	2
Neutropenia	2
Infection	2

Clinical Trial Locations for MAXIPIME

Trials by Country

Trials by Country for MAXIPIME
Location	Trials
Colombia	3
United States	2
Russian Federation	2
Egypt	1

Trials by US State

Trials by US State for MAXIPIME
Location	Trials
Texas	1
North Carolina	1

Clinical Trial Progress for MAXIPIME

Clinical Trial Phase

Clinical Trial Phase for MAXIPIME
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for MAXIPIME
Clinical Trial Phase	Trials
Terminated	2
Completed	2
Recruiting	1

Clinical Trial Sponsors for MAXIPIME

Sponsor Name

Sponsor Name for MAXIPIME
Sponsor	Trials
Hospital Santa Clara, Bogota	1
Assiut University	1
Hospital Simon Bolivar, Bogota	1

Sponsor Type

Sponsor Type for MAXIPIME
Sponsor	Trials
Other	14
Industry	2
NIH	1